Anticiper les conséquences de la non-conformité aux règles GMP sur la chaîne logistique de l'industrie pharmaceutique
Promotor(s) : Van Caillie, Didier
Date of defense : 4-Sep-2023/8-Sep-2023 • Permalink :
|Anticiper les conséquences de la non-conformité aux règles GMP sur la chaîne logistique de l'industrie pharmaceutique
|Date of defense :
|Van Caillie, Didier
|Committee's member(s) :
|Number of pages :
[en] Pharmaceutical industry
[en] Supply chain
|Business & economic sciences > Production, distribution & supply chain management
|Université de Liège, Liège, Belgique
|Master en sciences de gestion, à finalité spécialisée en global supply chain management
|Master thesis of the HEC-Ecole de gestion de l'Université de Liège
[en] This study examines the critical area of the pharmaceutical industry, focusing on the potential
ramifications stemming from non-compliance with Good Manufacturing Practice (GMP) regulations
within the supply chain. The objective is to analyze the repercussions of failing to adhere to GMP rules
and to provide an overview of anticipation and mitigation strategies.
The research emphasizes the significance of GMP compliance in safeguarding pharmaceutical product
quality, integrity, and safety throughout the supply chain. Drawing on a combination of regulatory
analysis, case studies, and input from industry stakeholders, the study provides a comprehensive view
of the potential consequences that can arise due to non-conformity with GMP regulations.
The anticipatory solutions proposed as part of thesis pertain to the measures outlined in this research
paper, which include relocation subcontractors closer to the market, diversifying suppliers, driving
internal and external audits, building strong partnerships with suppliers and logistics service providers,
using advanced tracking and traceability technologies, prioritizing customer satisfaction, managing
controlled safety stocks, ensuring managed business continuity in the event of supply chain
disruptions, and implementing rigorous staff training. A more comprehensive approach has been
considered by contemplating the integration of blockchain technology into the field. These
implications extend beyond the business realm, directly impacting patient safety and well-being.
However, it is important to recognize certain limitations of this study. The research focuses on a
limited sample of pharmaceutical companies, which potentially limits the generalizability of the
results. Variation in the application of GMP across different companies may introduce biases into the
analysis. In addition, the dynamic nature of external factors influencing the pharmaceutical industry
requires future research to comprehensively address all aspects.
Cite this master thesis
The University of Liège does not guarantee the scientific quality of these students' works or the accuracy of all the information they contain.